Search Orphan Drug Designations and Approvals
-
| Generic Name: | genetically modified CD34+ hematopoietic stem cells using a lentiviral vector carrying the beta A-T87Q-globin gene |
|---|---|
| Date Designated: | 07/11/2024 |
| Orphan Designation: | Treatment of beta-thalassemia |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Kanglin Biotechnology (Hangzhou) Co., Ltd. Room 301, Building No.4, No.291, Fucheng Road Hangzhou Economic and Technological Development Zone, Zhejiang Province China The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







